![]() Its business includes molecular tests for infectious diseases with single-analyte/low-plex real-time polymerase chain reaction (PCR) technology, as well as a solid multiplexing panel technology for pathogen identification. In a similarly high-value deal in Q2, DiaSorin paid $1.8 billion in cash to buy Luminex and its extensive test offerings in the infectious disease, respiratory, vector-borne, hospital-acquired and gastroenterology infection markets, as well as genetics products and women’s health diagnostics. The company’s Respiratory Pathogen Panels identify the most common viral and bacterial organisms associated with upper respiratory infection, including SARS-CoV-2, complementing Roche’s extensive portfolio of COVID-19 diagnostics solutions. GenMark’s ePlex system drives lab efficiency through streamlined order-to-reporting workflow and enables better patient outcomes by rapidly diagnosing a patient’s symptoms. The outlier in Q1 2021 in terms of deal value was Roche and its $1.83 billion all-cash purchase of GenMark Diagnostics in a transaction that will enhance Roche’s presence in the infectious disease diagnostics space (especially in respiratory and bloodstream infections) and bring the company into the syndromic testing market for the first time. 1 | Molecular diagnostics M&A deal activity in 2021 by quarter. There was a decrease in Q2 with seven deals together totaling $3.4 billion, but Q3 (three deals) and Q4 (five deals) did not even reach one billion dollars, with $300 million and $728 million in aggregate values, respectively (Fig. Deal activity in terms of both volume and value was strongest during Q1, with nine deals together valued at $4.5 billion (half the full-year total). In 2021, molecular diagnostics companies agreed to 24 mergers and acquisitions, which had an aggregate deal value of $9 billion versus $13.2 billion from only 8 transactions in 2020. Investors’ confidence was showcased through both public and private fundraising, particularly for personalized medicine and liquid biopsy-focused companies. Financings also saw an uptick in deal numbers as well as an increase in deal value compared to the previous year. In comparison to acquisition activity in the space in 2020, overall deal value for 2021 was lower, but deal volume tripled. ![]() Dealmaking was strong among molecular diagnostics (MDx) players during 2021 despite the continuation of the pandemic, with most merger and acquisition (M&A) transactions demonstrating either a pivot in a new direction or an enhancement of current portfolios.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |